PlainPharmaWatch

CMS Open Payments · Program Year 2024

Coherus Biosciences Inc.

Coherus Biosciences Inc. reported $2,156,469.53 in payments to 2,945 physicians and teaching hospitals across 3,396 transactions.

See the rankings → How this is sourced
$2.2M
Total payments
3,396
Transactions
2,945
Recipients
−$311.5K
General Payments vs PY2023

Coherus Biosciences Inc. reported $2,156,469.53 in payments to 2,945 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #434 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $732.25 per recipient across 4 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Coherus Biosciences Inc. pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#434
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
4
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Coherus Biosciences Inc.'s CMS-reported General Payments decreased by $311.5K (−46.3%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: COHERUS ONCOLOGY, INC.PY2023: COHERUS ONCOLOGY, INC.PY2024: Coherus Biosciences Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$673.3KPY2024$361.8K
PY2023
$673,277.16
PY2024
$361,768.79

How Coherus Biosciences Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Coherus Biosciences Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$2,156,470 Top 22% higher than 78% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Coherus Biosciences Inc.

Averaging $635.00 per transaction and $732.25 per recipient, Coherus Biosciences Inc.'s Program Year 2024 total comes to $2,156,469.53 across 3,396 transactions and 2,945 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #434 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 4-category general-payment breakdown below at $195.8K (9.1% of the company's reported total, 44 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 4 types of general payments, Coherus Biosciences Inc.'s largest category was "Compensation for Services Other Than Consulting" at $195.8K - 9.1% of the company's reported total.

How Coherus Biosciences Inc. divides its payments

Top payment categories by total reported dollar volume

1. Compensation for Services…$195.8K2. Food and Beverage$86.6K3. Honoraria$52.2K4. Travel and Lodging$27.2K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $195.8K 44
Food and Beverage $86.6K 2,808
Honoraria $52.2K 32
Travel and Lodging $27.2K 61

Recipient Concentration in General Payments

The five largest recipient relationships account for $128,014.84 (35.4%) of $361,768.79 in this company's General Payments records across 2,011 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Coherus Biosciences Inc.

The five named recipients with the highest reported General Payments from this company

Seenu Hariprasad$32.5KPanayiotis Savvides$31.9KKrzysztof Misiukiewicz$23.4KChaitali Nangia$22.0KShravan Kandula$18.2K
  1. 1

    Seenu Hariprasad

    $32,482.83 across 19 reported transactions

  2. 2

    Panayiotis Savvides

    $31,910.55 across 26 reported transactions

  3. 3

    Krzysztof Misiukiewicz

    $23,439.19 across 19 reported transactions

  4. 4

    Chaitali Nangia

    $21,955.93 across 13 reported transactions

  5. 5

    Shravan Kandula

    $18,226.34 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $635.00. Average per recipient: $732.25.

Total Amount

$2,156,469.53

Avg per Transaction

$635.00

Avg per Recipient

$732.25

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Coherus Biosciences Inc. Share

0.0%

#434 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Coherus Biosciences Inc.

Mentor Worldwide LLC

$2.1M 8,503 recipients

Akebia Therapeutics Inc

$2.2M 5,560 recipients

Mylan Pharmaceuticals Inc.

$2.2M 8 recipients

Laborie Medical Technologies Corp.

$2.2M 3,675 recipients

MML US, Inc.

$2.1M 2,581 recipients

SiteSaver Inc.

$2.2M 2 recipients

Frequently Asked Questions

How much did Coherus Biosciences Inc. pay to physicians and hospitals in 2024? ▾
Coherus Biosciences Inc. made $2,156,469.53 in payments to physicians and hospitals in Program Year 2024, across 3,396 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Coherus Biosciences Inc.? ▾
Coherus Biosciences Inc. made payments to 2,945 physicians and teaching hospitals in 2024. The average payment per recipient was $732.25.
What types of payments did Coherus Biosciences Inc. make? ▾
4 categories of general payment make up Coherus Biosciences Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $195.8K, representing 9.1% of the company's reported total.
How does Coherus Biosciences Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Coherus Biosciences Inc. ranks #434 by total payment amount.
What is the average payment size from Coherus Biosciences Inc.? ▾
Coherus Biosciences Inc.'s 3,396 transactions to 2,945 recipients in 2024 averaged $635.00 per transaction.
Where does the payment data for Coherus Biosciences Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Coherus Biosciences Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.